SUSAN HILSENBECK to Triazoles
This is a "connection" page, showing publications SUSAN HILSENBECK has written about Triazoles.
Connection Strength
0.074
-
An epigenomic approach to therapy for tamoxifen-resistant breast cancer. Cell Res. 2014 Jul; 24(7):809-19.
Score: 0.027
-
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol. 2013 May 10; 31(14):1726-31.
Score: 0.025
-
A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer. Breast Cancer Res Treat. 2011 Oct; 129(3):819-27.
Score: 0.022